Productive infection of primary human hepatocytes with SARS-CoV-2 induces antiviral and proinflammatory responses

被引:7
|
作者
Heinen, Natalie [1 ]
Khanal, Rajendra [2 ,3 ]
Westhoven, Saskia [1 ]
Kloehn, Mara [1 ]
Herrmann, Simon T. [1 ]
Herrmann, Maike [4 ]
Tuoc, Tran [5 ]
Ulmke, Pauline Antonie [5 ]
Nguyen, Hoang Duy [5 ]
Nguyen, Huu Phuc [5 ]
Steinmann, Eike [1 ,6 ]
Todt, Daniel [1 ,7 ]
Brown, Richard J. P. [1 ,4 ]
Sharma, Amar Deep [2 ,3 ]
Pfaender, Stephanie [1 ]
机构
[1] Ruhr Univ Bochum, Dept Mol & Med Virol, Bochum, Germany
[2] Hannover Med Sch, Dept Gastroenterol Hepatol Infect Dis & Endocrinol, Hannover, Germany
[3] Hannover Med Sch, REBIRTH Res Ctr Translat Regenerat Med, Res Grp RNA Therapeut & Liver Regenerat, Hannover, Germany
[4] Paul Ehrlich Inst, Div Vet Med, Langen, Germany
[5] Ruhr Univ Bochum, Dept Human Genet, Bochum, Germany
[6] German Ctr Infect Res DZIF, External Partner Site, Bochum, Germany
[7] European Virus Bioinformat Ctr EVBC, Jena, Germany
关键词
COVID-19; LIVER; CYTOKINES; HEPATOCYTE;
D O I
10.1136/gutjnl-2023-330961
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
We read with interest the article by Luxenburger and Thimme, summarising current knowledge about hepatic sequelae in the context of SARS-CoV-2 infection.1 As acute liver injury is observed in one-third of the patients with hospitalised COVID-192 3 and chronic liver disease is associated with higher mortality rates,4 a detailed understanding of hepatic susceptibility and dysfunction in the context of SARS-CoV-2 infection is of utmost importance. Previous studies have provided evidence of hepatic infection,5-7 however, the molecular mechanisms underlying acute liver injury associated with SARS-CoV-2 infection are not well understood. Here we show that primary human hepatocytes (PHH) can be productively infected with SARS-CoV-2. Donor-specific production kinetics were observed, with de novo viral secretion from PHH increasing in a time-dependent manner for four out of six donors (figure 1A). To explore virus replication and host gene dysregulation in parallel, Illumina sequencing of time point-matched infected and uninfected PHH was performed, followed by mapping to host and virus scaffolds. Increases in viral genome coverage over time corresponded to increasing rates of secreted virus (figure 1B). On the host side, detectable messenger RNA (mRNA) expression of known or suspected SARS-CoV-2 entry factors was observed for all PHH donors (figure 1C). Despite robust viral replication, host transcriptional responses were delayed until 72 hours post infection (hpi) and correlated with specific type III and interferon-β (IFN) induction in three donors (D1-3; termed reactive), while two donors remained unreactive, even though low levels of viral replication were observed (D4-5; figure 1C). These observations imply a viral replication threshold must be crossed to trigger robust host responses in PHH. Interestingly, one donor (D6; termed pre-activated) possessed abundant IFN-encoding transcripts independent of infection status or sampling time, resulting in high baseline interferon stimulated gene expression which prevented productive infection (figure 1A-C). Of note, similar to reactive donors at 72 hpi, IFN production in the pre-activated donor was also limited to IFN-β and IFNL1-4, suggesting hepatocytes are unable to produce additional IFN types/subtypes at meaningful levels. © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
引用
收藏
页数:4
相关论文
共 50 条
  • [21] Antiviral responses in a Jamaican fruit bat intestinal organoid model of SARS-CoV-2 infection
    Marziah Hashimi
    T. Andrew Sebrell
    Jodi F. Hedges
    Deann Snyder
    Katrina N. Lyon
    Stephanie D. Byrum
    Samuel G. Mackintosh
    Dan Crowley
    Michelle D. Cherne
    David Skwarchuk
    Amanda Robison
    Barkan Sidar
    Anja Kunze
    Emma K. Loveday
    Matthew P. Taylor
    Connie B. Chang
    James N. Wilking
    Seth T. Walk
    Tony Schountz
    Mark A. Jutila
    Diane Bimczok
    Nature Communications, 14
  • [22] Single cell resolution of SARS-CoV-2 tropism, antiviral responses, and susceptibility to therapies in primary human airway epithelium
    Fiege, Jessica K.
    Thiede, Joshua M.
    Nanda, Hezkiel Arya
    Matchett, William E.
    Moore, Patrick J.
    Montanari, Noe Rico
    Thielen, Beth K.
    Daniel, Jerry
    Stanley, Emma
    Hunter, Ryan C.
    Menachery, Vineet D.
    Shen, Steven S.
    Bold, Tyler D.
    Langlois, Ryan A.
    PLOS PATHOGENS, 2021, 17 (01)
  • [23] Conjunctival epithelial cells resist productive SARS-CoV-2 infection
    Jackson, Robert M.
    Hatton, Catherine F.
    Spegarova, Jarmila Stremenova
    Georgiou, Maria
    Collin, Joseph
    Stephenson, Emily
    Verdon, Bernard
    Haq, Iram J.
    Hussain, Rafiqul
    Coxhead, Jonathan M.
    Mudhar, Hardeep-Singh
    Wagner, Bart
    Hasoon, Megan
    Davey, Tracey
    Rooney, Paul
    Khan, C. M. Anjam
    Ward, Chris
    Brodlie, Malcolm
    Haniffa, Muzlifah
    Hambleton, Sophie
    Armstrong, Lyle
    Figueiredo, Francisco
    Queen, Rachel
    Duncan, Christopher J. A.
    Lako, Majlinda
    STEM CELL REPORTS, 2022, 17 (07): : 1699 - 1713
  • [24] Conjunctival epithelial cells resist productive SARS-CoV-2 infection
    Lako, Majlinda
    Jackson, Robert
    Hatton, Catherine
    Spegarova, Jarmila
    Georgiou, Maria
    Collin, Joseph
    Stephenson, Emily
    Mudhar, Hardeep-Singh
    Wagner, Bart
    Rooney, Paul
    Haniffa, Muzlifah Haniffa
    Armstrong, Lyle
    Figueiredo, Francisco C.
    Queen, Rachel
    Duncan, Christopher
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2022, 63 (07)
  • [25] SARS-CoV-2 Antiviral Therapy
    Tao, Kaiming
    Tzou, Philip L.
    Nouhin, Janin
    Bonilla, Hector
    Jagannathan, Prasanna
    Shafer, Robert W.
    CLINICAL MICROBIOLOGY REVIEWS, 2021, 34 (04)
  • [26] SARS-CoV-2 infection induces beta cell transdifferentiation
    Tang, Xuming
    Uhl, Skyler
    Zhang, Tuo
    Xue, Dongxiang
    Li, Bo
    Vandana, J. Jeya
    Acklin, Joshua A.
    Bonnycastle, Lori L.
    Narisu, Narisu
    Erdos, Michael R.
    Bram, Yaron
    Chandar, Vasuretha
    Chong, Angie Chi Nok
    Lacko, Lauretta A.
    Min, Zaw
    Lim, Jean K.
    Borczuk, Alain C.
    Xiang, Jenny
    Naji, Ali
    Collins, Francis S.
    Evans, Todd
    Liu, Chengyang
    TenOever, Benjamin R.
    Schwartz, Robert E.
    Chen, Shuibing
    CELL METABOLISM, 2021, 33 (08) : 1577 - +
  • [27] SARS-CoV-2 infection induces robust mucosal antibody responses in the upper respiratory tract
    Escalera, Alba
    Rojo-Fernandez, Amaya
    Rombauts, Alexander
    Abelenda-Alonso, Gabriela
    Carratala, Jordi
    Garcia-Sastre, Adolfo
    Aydillo, Teresa
    ISCIENCE, 2024, 27 (03)
  • [28] Antiviral Product in early SARS-COV-2 Infection - for whom and when?
    Klein, Friederike
    PNEUMOLOGIE, 2022, 76 (06):
  • [29] Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review
    Gil Martinez, Victoria
    Avedillo Salas, Ana
    Santander Ballestin, Sonia
    PHARMACEUTICALS, 2021, 14 (08)
  • [30] SARS-CoV-2 virus infection: Targets and antiviral pharmacological strategies
    de Oliveira Campos, Daniel Melo
    Fulco, Umberto Laino
    Silva de Oliveira, Claudio Bruno
    Nobre Oliveira, Jonas Ivan
    JOURNAL OF EVIDENCE BASED MEDICINE, 2020, 13 (04) : 255 - 260